Patent intelligence · US
US 11220535
Anti-BCMA chimeric antigen receptors
Anti-BCMA chimeric antigen receptors
Patent details — US 11220535
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 11, 2022
- Expiration
- Jan 6, 2042
- Applicant
- Cartesian Therapeutics, Inc.
- Claims
- 30
- CPC classes
- A61K, A61K2039/505, A61K2239/46, A61K38/00
Quick answer
US 11220535 (Anti-BCMA chimeric antigen receptors) is held by Cartesian Therapeutics, Inc.. Status: granted. Granted Jan 11, 2022. Expires Jan 6, 2042 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Cartesian Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 30
- CPC classes
- A61K, A61K2039/505, A61K2239/46, A61K38/00, A61K39/3955, A61K39/39558
More from Cartesian Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11220535?
US 11220535 (Anti-BCMA chimeric antigen receptors) is held by Cartesian Therapeutics, Inc.. Status: granted. Granted Jan 11, 2022. Expires Jan 6, 2042 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11220535?
Cartesian Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 11220535 expire?
Our index shows an expiration date of Jan 6, 2042 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.